爱博泰克完成12亿元D轮融资;成都赜灵完成亿元A轮融资;康恩贝16.8亿元出让珍视明42%股权

2022-11-21
338
97

Author:Ebotec completed the round D financing of 1.2 billion yuan; Chengdu Geling completed a round A financing of 100 million yuan; Kang'enbei transferred 42% equity of Zhenshiming with 1.68 billion yuan
Source: iResearch

Introduction:Ebotec completed the round D financing of 1.2 billion yuan; Chengdu Geling completed a round A financing of 100 million yuan; Kang'enbei transferred 42% equity of Zhenshiming with 1.68 billion yuan

[Investment and Financing News DecembereightDay]Ebotec focuses on the construction of antibody platform and protein platform, and continuously introduces advanced antibody and protein technology to optimize the two platforms. The antibody platform includes rabbit polyclonal antibody platform, mouse monoclonal antibody platform and the newly introduced rabbit monoclonal antibody platform. Recently completed the D round of 1.2 billion yuanfinancing

It is a familyinnovateDrug R&D and industrialization service providers,companyThe R&D pipeline covers the R&D of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by novel coronavirus pneumonia. Recently, the financing scale reached 106.5 million yuan in round A financing.

Zhenshiming Pharmaceutical Co., Ltd. is a manufacturer of Chinese and western medicine preparations. It has more than 40 varieties of eye drops, 6 products that have entered the national basic drug catalog, and 25 national medical insurance products. The total amount of equity financing completed a few days ago was 1.68 billion yuan.

Cross border information investment and financing news | Ebotec completed the round D financing of 1.2 billion yuan; Chengdu Geling completed a round A financing of 100 million yuan; Kang'enbei transferred 42% equity of Zhenshiming with 1.68 billion yuan

(This document isIrinetFor the reprint of exclusive original manuscript, please indicate the source)
The content of the article is created by the author, and the author is responsible for the authenticity, accuracy and legality of the content. Overseadia advocates respecting and protecting intellectual property rights. Without the permission of the author and/or this website, the content of this website may not be copied, reproduced, or used in other ways. If you find that there are copyright issues in the articles on this site, please contact chuhaiyi@baidu.com, and we will verify and deal with them in time. Source of the article: iResearch, this article is the author's independent point of view, and does not represent the position of overseadia.